These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35027405)

  • 21. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
    Weitz JI; Szekanecz Z; Charles-Schoeman C; Vranic I; Sahin B; Paciga SA; Wang Z; Hyde C; Martin DA
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36323490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F; Yun H; Bernatsky S; Curtis JR
    Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
    Song GG; Bae SC; Lee YH
    Korean J Intern Med; 2014 Sep; 29(5):656-63. PubMed ID: 25228842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy.
    D'Alessandro F; Cazzato M; Laurino E; Morganti R; Bardelli M; Frediani B; Buongarzone C; Moroncini G; Guiducci S; Cometi L; Benucci M; Ligobbi F; Marotto D; Mosca M
    Clin Rheumatol; 2024 Feb; 43(2):657-665. PubMed ID: 38135860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
    Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
    Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
    Harnett J; Gerber R; Gruben D; Koenig AS; Chen C
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a
    Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
    Chopra A; Shobha V; Chandrashekara S; Veeravalli SCM; Sharma R; Rao UR; Pandya S; Wagh S; Kadel JK; Thorat AV; Adhav C; Santos Estrella P; Yu W; Kwok K; Wouters A
    Int J Rheum Dis; 2020 Jul; 23(7):882-897. PubMed ID: 32478474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
    Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
    J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
    Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R
    Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
    Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
    Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate Combination.
    Cohen SB; Haraoui B; Curtis JR; Smith TW; Woolcott J; Gruben D; Murray CW
    Clin Ther; 2022 Jul; 44(7):982-997.e2. PubMed ID: 35667900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
    Clowse ME; Feldman SR; Isaacs JD; Kimball AB; Strand V; Warren RB; Xibillé D; Chen Y; Frazier D; Geier J; Proulx J; Marren A
    Drug Saf; 2016 Aug; 39(8):755-62. PubMed ID: 27282428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.